News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

The DHS guidelines on essential critical infrastructure updated to include lab personnel working outside COVID-19

In previous publications, the CISA guidance was limited to, “Workers conducting research critical to COVID-19 response”. The new version also includes “Workers, including lab personnel who perform critical biomedical research, development, and testing, needed for COVID-19 response or other diseases”. For complete details we have provided the publication:


EAD Logo
Taking too long?

Reload Reload document

Open Open in new tab

Download […]

OMEP announces potential funding to manufacturers

Oregon Manufacturing Extension Partnership (OMEP), shares  that through its membership in Manufacturing USA Institutes (MUSA) ARM (Advanced Robotics for Manufacturing),OMEP can provide funding to manufacturers who are responding to COVID-19.

April 14, 2020 |

Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

 Osaka, JAPAN, and King of Prussia, PA, USA – April 6, 2020  Biotest, BPL Group, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin […]

April 7, 2020 |

Gilead clinical trial sites in Oregon that are currently enrolling

When the news of the coronavirus first emerged, Gilead immediately began to consider the potential of remdesivir, an investigational antiviral in development. The responsibility is to ensure that remdesivir is effective and safe before it is distributed for use worldwide. Multiple clinical trials are ongoing.

NemaMetrix expands business to capitalize on In-vivo solutions to help speed testing for critical disease therapeutics

Company Changes Operating Name to InVivo Biosystems

Eugene, Ore. – March 31, 2020 – NemaMetrix is changing its operating name to InVivo Biosystems as the company expands its research platforms to accelerate deep in-vivo insights that help researchers develop and deliver therapeutic solutions for critical diseases. The company’s solutions now provide essential services to pharmaceutical, nutraceuticals, and biotechnology companies around the world to speed research and drug development efforts, enabling earlier insights by closing the gap between cells and mice. The company’s new capabilities help […]

COVID-19: Oregon Bio culls subject matter and resource experts

Oregon Bio, as a service to members during this time of COVID-19, is developing a list of experts in subject matter and resources who have local expertise in inventory, supply, research and potential availability of resources including PPE, research capabilities and needed infrastructure, supplies/inventories, testing kit components, and care treatment and protocols. Please send your information, contact details and description of your expertise to

Subject matter experts are also being culled from the 

RSS Error: WP HTTP Error: cURL error 28: Operation timed out after 10003 milliseconds with 0 bytes received